Global epidemiology of heart failure.
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
accepted:
28
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Heart failure (HF) is a heterogeneous clinical syndrome marked by substantial morbidity and mortality. The natural history of HF is well established; however, epidemiological data are continually evolving owing to demographic shifts, advances in treatment and variations in access to health care. Although the incidence of HF has stabilized or declined in high-income countries over the past decade, its prevalence continues to increase, driven by an ageing population, an increase in risk factors, the effectiveness of novel therapies and improved survival. This rise in prevalence is increasingly noted among younger adults and is accompanied by a shift towards HF with preserved ejection fraction. However, disparities exist in our epidemiological understanding of HF burden and progression in low-income and middle-income countries owing to the lack of comprehensive data in these regions. Therefore, the current epidemiological landscape of HF highlights the need for periodic surveillance and resource allocation tailored to geographically vulnerable areas. In this Review, we highlight global trends in the burden of HF, focusing on the variations across the spectrum of left ventricular ejection fraction. We also discuss evolving population-based estimates of HF incidence and prevalence, the risk factors for and aetiologies of this disease, and outcomes in different geographical regions and populations.
Identifiants
pubmed: 38926611
doi: 10.1038/s41569-024-01046-6
pii: 10.1038/s41569-024-01046-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30–41 (2011).
pubmed: 21060326
doi: 10.1038/nrcardio.2010.165
Dunlay, S. M. et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 140, e294–e324 (2019).
pubmed: 31167558
doi: 10.1161/CIR.0000000000000691
Yan, T. et al. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 Study. J. Am. Heart Assoc. 12, e027852 (2023).
pubmed: 36892088
pmcid: 10111559
doi: 10.1161/JAHA.122.027852
Mamas, M. A. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur. J. Heart Fail. 19, 1095–1104 (2017).
pubmed: 28470962
doi: 10.1002/ejhf.822
Jones, N. R., Roalfe, A. K., Adoki, I., Hobbs, F. D. R. & Taylor, C. J. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur. J. Heart Fail. 21, 1306–1325 (2019).
pubmed: 31523902
doi: 10.1002/ejhf.1594
Jones, N. R., Hobbs, F. R. & Taylor, C. J. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open 1, bjgpopen17X101013 (2017).
pubmed: 30564675
pmcid: 6169931
doi: 10.3399/bjgpopen17X101013
Savarese, G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 118, 3272–3287 (2023).
pubmed: 35150240
doi: 10.1093/cvr/cvac013
Seferović, P. M. et al. The heart failure association atlas: heart failure epidemiology and management statistics 2019. Eur. J. Heart Fail. 23, 906–914 (2021).
pubmed: 33634931
doi: 10.1002/ejhf.2143
Virani, S. S. et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 143, e254–e743 (2021).
pubmed: 33501848
doi: 10.1161/CIR.0000000000000950
Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14, 591–602 (2017).
pubmed: 28492288
doi: 10.1038/nrcardio.2017.65
McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 24, 4–131 (2022).
pubmed: 35083827
doi: 10.1002/ejhf.2333
Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur. J. Heart Fail. 23, 352–380 (2021).
pubmed: 33605000
doi: 10.1002/ejhf.2115
McKee, P. A., Castelli, W. P., McNamara, P. M. & Kannel, W. B. The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med. 285, 1441–1446 (1971).
pubmed: 5122894
doi: 10.1056/NEJM197112232852601
Carlson, K. J., Lee, D. C., Goroll, A. H., Leahy, M. & Johnson, R. A. An analysis of physicians’ reasons for prescribing long-term digitalis therapy in outpatients. J. Chronic Dis. 38, 733–739 (1985).
pubmed: 4030999
doi: 10.1016/0021-9681(85)90115-8
Eriksson, H. et al. Cardiac and pulmonary causes of dyspnoea-validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. Eur. Heart J. 8, 1007–1014 (1987).
pubmed: 3665952
doi: 10.1093/oxfordjournals.eurheartj.a062365
Swedberg, K. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Heart J. 26, 1115–1140 (2005).
pubmed: 15901669
doi: 10.1093/eurheartj/ehi204
Hunt, S. A. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 38, 2101–2113 (2001).
pubmed: 11738322
doi: 10.1016/S0735-1097(01)01683-7
Crespo-Leiro, M. G. et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 20, 1505–1535 (2018).
pubmed: 29806100
doi: 10.1002/ejhf.1236
Khan, M. S., Shahid, I., Fonarow, G. C. & Greene, S. J. Classifying heart failure based on ejection fraction: imperfect but enduring. Eur. J. Heart Fail. 24, 1154–1157 (2022).
pubmed: 35239210
doi: 10.1002/ejhf.2470
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022).
pubmed: 35363499
Greenberg, B., O’Connor, C. M. & Felker, G. M. Classifying heart failure in the 21st century: matching taxonomy with science. JACC Heart Fail. 9, 771–773 (2021).
pubmed: 34593202
doi: 10.1016/j.jchf.2021.08.004
Atherton, J. J. et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 27, 1123–1208 (2018).
pubmed: 30077227
doi: 10.1016/j.hlc.2018.06.1042
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).
doi: 10.1016/S0140-6736(20)30925-9
Government of Canada. Canadian Chronic Disease Surveillance System (CCDSS). Trend Over Time https://health-infobase.canada.ca/ccdss/data-tool (2024).
Anguita Sánchez, M. et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev. Esp. Cardiol. 61, 1041–1049 (2008).
pubmed: 18817680
doi: 10.1157/13126044
Farré, N. et al. Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients. PLoS One 12, e0172745 (2017).
pubmed: 28235067
pmcid: 5325273
doi: 10.1371/journal.pone.0172745
Camps-Vilaró, A. et al. Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF study criteria. J. Clin. Med. 9, 2089 (2020).
pubmed: 32635219
pmcid: 7408645
doi: 10.3390/jcm9072089
González-Juanatey, J. R. et al. Heart failure in outpatients: comorbidities and management by different specialists. The EPISERVE Study [Spanish]. Rev. Esp. Cardiol. 61, 611–619 (2008).
pubmed: 18570782
doi: 10.1157/13123067
Störk, S. et al. Epidemiology of heart failure in Germany: a retrospective database study. Clin. Res. Cardiol. 106, 913–922 (2017).
pubmed: 28748265
pmcid: 5655572
doi: 10.1007/s00392-017-1137-7
Piccinni, C. et al. The burden of chronic heart failure in primary care in Italy. High Blood Press. Cardiovasc. Prev. 24, 171–178 (2017).
pubmed: 28324597
doi: 10.1007/s40292-017-0193-4
Buja, A. et al. Prevalence of heart failure and adherence to process indicators: which socio-demographic determinants are involved? Int. J. Env. Res. Public Health 13, 238 (2016).
doi: 10.3390/ijerph13020238
Bellanca, L., Linden, S. & Farmer, R. Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data — the PULSE study. BMC Cardiovasc. Disord. 23, 374 (2023).
pubmed: 37495953
pmcid: 10373419
doi: 10.1186/s12872-023-03337-1
Heart Failure Policy Network. Heart Failure Policy and Practice in Europe: France www.hfpolicynetwork.org/wp-content/uploads/Heart-failure-policy-and-practice-in-Europe-France.pdf (2020).
Cheng, R. K. et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am. Heart J. 168, 721–730 (2014).
pubmed: 25440801
doi: 10.1016/j.ahj.2014.07.008
Fonarow, G. C. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J. Am. Coll. Cardiol. 50, 768–777 (2007).
pubmed: 17707182
doi: 10.1016/j.jacc.2007.04.064
Koh, A. S. et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 19, 1624–1634 (2017).
pubmed: 28948683
doi: 10.1002/ejhf.945
Chioncel, O. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur. J. Heart Fail. 19, 1574–1585 (2017).
pubmed: 28386917
doi: 10.1002/ejhf.813
Gavina, C. et al. 20 years of real-world data to estimate the prevalence of heart failure and its subtypes in an unselected population of integrated care units. J. Cardiovasc. Dev. Dis. 9, 149 (2022).
pubmed: 35621860
pmcid: 9146196
National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) https://www.cdc.gov/nchs/nhanes/index.htm (2024).
Bozkurt, B. et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure Society of America. J. Card. Fail. 29, 1412–1451 (2023).
pubmed: 37797885
pmcid: 10864030
doi: 10.1016/j.cardfail.2023.07.006
Bragazzi, N. L. et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur. J. Prev. Cardiol. 28, 1682–1690 (2021).
pubmed: 33571994
doi: 10.1093/eurjpc/zwaa147
Ceia, F. et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 4, 531–539 (2002).
pubmed: 12167394
doi: 10.1016/S1388-9842(02)00034-X
Rethy, L. et al. Trends in the prevalence of self-reported heart failure by race/ethnicity and age from 2001 to 2016. JAMA Cardiol. 5, 1425–1429 (2020).
pubmed: 32876652
doi: 10.1001/jamacardio.2020.3654
Bovet, P. & Paccaud, F. Cardiovascular disease and the changing face of global public health: a focus on low and middle income countries. Public Health Rev. 33, 397–415 (2011).
doi: 10.1007/BF03391643
World Population Review. 2020 World Population by Country https://worldpopulationreview.com/ (2020).
Martinez-Amezcua, P. et al. The upcoming epidemic of heart failure in South Asia. Circ. Heart Fail. 13, e007218 (2020).
pubmed: 32962410
doi: 10.1161/CIRCHEARTFAILURE.120.007218
Feng, J., Zhang, Y. & Zhang, J. Epidemiology and burden of heart failure in Asia. JACC Asia 4, 249–264 (2024).
pubmed: 38660101
pmcid: 11035951
doi: 10.1016/j.jacasi.2024.01.013
Reyes, E. B. et al. Heart failure across Asia: same healthcare burden but differences in organization of care. Int. J. Cardiol. 223, 163–167 (2016).
pubmed: 27541646
doi: 10.1016/j.ijcard.2016.07.256
Hao, G. et al. Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012-2015. Eur. J. Heart Fail. 21, 1329–1337 (2019).
pubmed: 31746111
doi: 10.1002/ejhf.1629
Konishi, M. et al. Heart failure epidemiology and novel treatments in Japan: facts and numbers. Esc. Heart Fail. 3, 145–151 (2016).
pubmed: 27840692
pmcid: 5096253
doi: 10.1002/ehf2.12103
Sahle, B. W., Owen, A. J., Mutowo, M. P., Krum, H. & Reid, C. M. Prevalence of heart failure in Australia: a systematic review. BMC Cardiovasc. Disord. 16, 32 (2016).
pubmed: 26852410
pmcid: 4744379
doi: 10.1186/s12872-016-0208-4
Shiga, T. et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. Esc. Heart Fail. 6, 475–486 (2019).
pubmed: 30829002
pmcid: 6487690
doi: 10.1002/ehf2.12418
MacDonald, M. R. et al. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF registry. J. Am. Heart Assoc. 9, e012199 (2020).
pubmed: 31852421
doi: 10.1161/JAHA.119.012199
Ciapponi, A. et al. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev. Esp. Cardiol. 69, 1051–1060 (2016).
pubmed: 27553287
doi: 10.1016/j.recesp.2016.04.045
Karaye, K. M. et al. Clinical profiles and outcomes of heart failure in five African countries: results from INTER-CHF study. Glob. Heart 16, 50 (2021).
pubmed: 34381672
pmcid: 8323533
doi: 10.5334/gh.940
Gerber, Y. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175, 996–1004 (2015).
pubmed: 25895156
pmcid: 4451405
doi: 10.1001/jamainternmed.2015.0924
Khera, R. et al. Temporal trends in heart failure incidence among medicare beneficiaries across risk factor strata, 2011 to 2016. JAMA Netw. Open 3, e2022190 (2020).
pubmed: 33095250
pmcid: 7584929
doi: 10.1001/jamanetworkopen.2020.22190
Tsao, C. W. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 6, 678–685 (2018).
pubmed: 30007560
pmcid: 6076350
doi: 10.1016/j.jchf.2018.03.006
Corrao, G., Ghirardi, A., Ibrahim, B., Merlino, L. & Maggioni, A. P. Burden of new hospitalization for heart failure: a population-based investigation from Italy. Eur. J. Heart Fail. 16, 729–736 (2014).
pubmed: 24806352
doi: 10.1002/ejhf.105
Zarrinkoub, R. et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur. J. Heart Fail. 15, 995–1002 (2013).
pubmed: 23645498
doi: 10.1093/eurjhf/hft064
Conrad, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391, 572–580 (2018).
pubmed: 29174292
pmcid: 5814791
doi: 10.1016/S0140-6736(17)32520-5
Smeets, M. et al. Burden of heart failure in Flemish general practices: a registry-based study in the Intego database. BMJ Open 9, e022972 (2019).
pubmed: 30617099
pmcid: 6326340
doi: 10.1136/bmjopen-2018-022972
Christiansen, M. N. et al. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation 135, 1214–1223 (2017).
pubmed: 28174193
doi: 10.1161/CIRCULATIONAHA.116.025941
Huffman, M. D. et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J. Am. Coll. Cardiol. 61, 1510–1517 (2013).
pubmed: 23500287
pmcid: 3618527
doi: 10.1016/j.jacc.2013.01.022
Magnussen, C. et al. Sex-specific epidemiology of heart failure risk and mortality in Europe: results from the BiomarCaRE consortium. JACC Heart Fail. 7, 204–213 (2019).
pubmed: 30819375
doi: 10.1016/j.jchf.2018.08.008
Ødegaard, K. M., Hallén, J., Lirhus, S. S., Melberg, H. O. & Halvorsen, S. Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. Esc. Heart Fail. 7, 1917–1926 (2020).
pubmed: 32530563
pmcid: 7373922
doi: 10.1002/ehf2.12773
Bleumink, G. S. et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart J. 25, 1614–1619 (2004).
pubmed: 15351160
doi: 10.1016/j.ehj.2004.06.038
Bahrami, H. et al. Differences in the incidence of congestive heart failure by ethnicity: the Multi-Ethnic Study of Atherosclerosis. Arch. Intern. Med. 168, 2138–2145 (2008).
pubmed: 18955644
pmcid: 3038918
doi: 10.1001/archinte.168.19.2138
Roberts, C. B. et al. Influence of life-course socioeconomic position on incident heart failure in blacks and whites: the atherosclerosis risk in communities study. Am. J. Epidemiol. 172, 717–727 (2010).
pubmed: 20696652
pmcid: 2950818
doi: 10.1093/aje/kwq193
Gottdiener, J. S. et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 35, 1628–1637 (2000).
pubmed: 10807470
doi: 10.1016/S0735-1097(00)00582-9
Liew, D. et al. Epidemiology of heart failure: Study of Heart failure in the Australian Primary carE setting (SHAPE). Esc. Heart Fail. 7, 3871–3880 (2020).
pubmed: 32902206
pmcid: 7754764
doi: 10.1002/ehf2.12979
Wang, H. et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ. Heart Fail. 14, e008406 (2021).
pubmed: 34455858
doi: 10.1161/CIRCHEARTFAILURE.121.008406
Huffman, M. D. & Prabhakaran, D. Heart failure: epidemiology and prevention in India. Natl Med. J. India 23, 283–288 (2010).
pubmed: 21250584
pmcid: 3913650
Dunlay, S. M., Weston, S. A., Jacobsen, S. J. & Roger, V. L. Risk factors for heart failure: a population-based case-control study. Am. J. Med. 122, 1023–1028 (2009).
pubmed: 19854330
pmcid: 2789475
doi: 10.1016/j.amjmed.2009.04.022
Bursi, F. et al. Systolic and diastolic heart failure in the community. JAMA 296, 2209–2216 (2006).
pubmed: 17090767
doi: 10.1001/jama.296.18.2209
Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251–259 (2006).
pubmed: 16855265
doi: 10.1056/NEJMoa052256
Gustafsson, F. et al. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur. Heart J. 24, 863–870 (2003).
pubmed: 12727154
doi: 10.1016/S0195-668X(02)00845-X
Dewan, P. et al. Sex-related differences in heart failure with preserved ejection fraction. Circ. Heart Fail. 12, e006539 (2019).
pubmed: 31813280
doi: 10.1161/CIRCHEARTFAILURE.119.006539
Regitz-Zagrosek, V. Sex and gender differences in heart failure. Int. J. Heart Fail. 2, 157–181 (2020).
pubmed: 36262368
pmcid: 9536682
doi: 10.36628/ijhf.2020.0004
Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B. & Ho, K. K. The progression from hypertension to congestive heart failure. JAMA 275, 1557–1562 (1996).
pubmed: 8622246
doi: 10.1001/jama.1996.03530440037034
Kannel, W. B., Hjortland, M. & Castelli, W. P. Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29–34 (1974).
pubmed: 4835750
doi: 10.1016/0002-9149(74)90089-7
Triposkiadis, F., Xanthopoulos, A. & Butler, J. Cardiovascular aging and heart failure: JACC review topic of the week. J. Am. Coll. Cardiol. 74, 804–813 (2019).
pubmed: 31395131
doi: 10.1016/j.jacc.2019.06.053
Rethy, L. et al. Contemporary rates of hospitalization for heart failure in young and middle-aged adults in a diverse US State. Circ. Cardiovasc. Qual. Outcomes 13, e007014 (2020).
pubmed: 33176466
pmcid: 7674232
doi: 10.1161/CIRCOUTCOMES.120.007014
Czepluch, F. S., Wollnik, B. & Hasenfuß, G. Genetic determinants of heart failure: facts and numbers. Esc. Heart Fail. 5, 211–217 (2018).
pubmed: 29457878
pmcid: 5933969
doi: 10.1002/ehf2.12267
Tayal, U., Prasad, S. & Cook, S. A. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 9, 20 (2017).
pubmed: 28228157
pmcid: 5322656
doi: 10.1186/s13073-017-0410-8
Haas, J. et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur. Heart J. 36, 1123–1135 (2015).
pubmed: 25163546
doi: 10.1093/eurheartj/ehu301
Rosenbaum, A. N., Agre, K. E. & Pereira, N. L. Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nat. Rev. Cardiol. 17, 286–297 (2020).
pubmed: 31605094
doi: 10.1038/s41569-019-0284-0
Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129–2200 (2016).
pubmed: 27206819
doi: 10.1093/eurheartj/ehw128
Arbelo, E. et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur. Heart J. 44, 3503–3626 (2023).
pubmed: 37622657
doi: 10.1093/eurheartj/ehad194
NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 394, 639–651 (2019).
pmcid: 6717084
doi: 10.1016/S0140-6736(19)31145-6
Yancy, C. W., Lopatin, M., Stevenson, L. W., De Marco, T. & Fonarow, G. C. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 47, 76–84 (2006).
pubmed: 16386668
doi: 10.1016/j.jacc.2005.09.022
Dokainish, H. et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob. Health 5, e665–e672 (2017).
pubmed: 28476564
doi: 10.1016/S2214-109X(17)30196-1
Savarese, G. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 61, 131–142 (2013).
pubmed: 23219304
doi: 10.1016/j.jacc.2012.10.011
Ather, S. et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J. Am. Coll. Cardiol. 59, 998–1005 (2012).
pubmed: 22402071
pmcid: 4687406
doi: 10.1016/j.jacc.2011.11.040
Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241, 2035–2038 (1979).
pubmed: 430798
doi: 10.1001/jama.1979.03290450033020
Bahrami, H. et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J. Am. Coll. Cardiol. 51, 1775–1783 (2008).
pubmed: 18452784
doi: 10.1016/j.jacc.2007.12.048
Preiss, D. et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 32, 915–920 (2009).
pubmed: 19196892
pmcid: 2671104
doi: 10.2337/dc08-1709
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A. & Brown, J. B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27, 1879–1884 (2004).
pubmed: 15277411
doi: 10.2337/diacare.27.8.1879
Bertoni, A. G. et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27, 699–703 (2004).
pubmed: 14988288
doi: 10.2337/diacare.27.3.699
Bibbins-Domingo, K. et al. Predictors of heart failure among women with coronary disease. Circulation 110, 1424–1430 (2004).
pubmed: 15353499
doi: 10.1161/01.CIR.0000141726.01302.83
Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113, 359–364 (2002).
pubmed: 12401529
doi: 10.1016/S0002-9343(02)01236-6
Kotecha, D. & Piccini, J. P. Atrial fibrillation in heart failure: what should we do? Eur. Heart J. 36, 3250–3257 (2015).
pubmed: 26419625
pmcid: 4670966
Packer, M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur. J. Heart Fail. 22, 214–227 (2020).
pubmed: 31849132
doi: 10.1002/ejhf.1646
Sartipy, U., Dahlström, U., Fu, M. & Lund, L. H. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 5, 565–574 (2017).
pubmed: 28711451
doi: 10.1016/j.jchf.2017.05.001
Patel, R. B., Vaduganathan, M., Shah, S. J. & Butler, J. Atrial fibrillation in heart failure with preserved ejection fraction: insights into mechanisms and therapeutics. Pharmacol. Ther. 176, 32–39 (2017).
pubmed: 27773787
doi: 10.1016/j.pharmthera.2016.10.019
Carlisle, M. A., Fudim, M., DeVore, A. D. & Piccini, J. P. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 7, 447–456 (2019).
pubmed: 31146871
doi: 10.1016/j.jchf.2019.03.005
Axson, E. L. et al. Temporal trends in the incidence of heart failure among patients with chronic obstructive pulmonary disease and its association with mortality. Ann. Am. Thorac. Soc. 17, 939–948 (2020).
pubmed: 32275836
doi: 10.1513/AnnalsATS.201911-820OC
Hawkins, N. M. et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur. J. Heart Fail. 11, 130–139 (2009).
pubmed: 19168510
pmcid: 2639415
doi: 10.1093/eurjhf/hfn013
Segall, L., Nistor, I. & Covic, A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed. Res. Int. 2014, 937398 (2014).
pubmed: 24959595
pmcid: 4052068
doi: 10.1155/2014/937398
Löfman, I., Szummer, K., Dahlström, U., Jernberg, T. & Lund, L. H. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur. J. Heart Fail. 19, 1606–1614 (2017).
pubmed: 28371075
doi: 10.1002/ejhf.821
Zelnick, L. R. et al. Prediction of incident heart failure in CKD: the CRIC study. Kidney Int. Rep. 7, 708–719 (2022).
pubmed: 35497796
pmcid: 9039424
doi: 10.1016/j.ekir.2022.01.1067
Kottgen, A. et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 18, 1307–1315 (2007).
pubmed: 17344421
doi: 10.1681/ASN.2006101159
Saran, R. et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 75, A6–A7 (2020).
pubmed: 31704083
doi: 10.1053/j.ajkd.2019.09.003
House, A. A. et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 95, 1304–1317 (2019).
pubmed: 31053387
doi: 10.1016/j.kint.2019.02.022
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387, 1377–1396 (2016).
doi: 10.1016/S0140-6736(16)30054-X
Ho, J. E. et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ. Heart Fail. 6, 279–286 (2013).
pubmed: 23271790
doi: 10.1161/CIRCHEARTFAILURE.112.972828
Pandey, A. et al. Relationship between physical activity, body mass index, and risk of heart failure. J. Am. Coll. Cardiol. 69, 1129–1142 (2017).
pubmed: 28254175
pmcid: 5848099
doi: 10.1016/j.jacc.2016.11.081
Morricone, L. et al. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes. Res. 10, 489–498 (2002).
pubmed: 12055325
doi: 10.1038/oby.2002.67
Horwich, T. B. & Fonarow, G. C. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J. Am. Coll. Cardiol. 55, 283–293 (2010).
pubmed: 20117431
pmcid: 2834416
doi: 10.1016/j.jacc.2009.07.029
Hamzeh, N., Ghadimi, F., Farzaneh, R. & Hosseini, S. K. Obesity, heart failure, and obesity paradox. J. Tehran Heart Cent. 12, 1–5 (2017).
pubmed: 28469684
pmcid: 5409942
Horwich, T. B., Fonarow, G. C. & Clark, A. L. Obesity and the obesity paradox in heart failure. Prog. Cardiovasc. Dis. 61, 151–156 (2018).
pubmed: 29852198
doi: 10.1016/j.pcad.2018.05.005
Powell-Wiley, T. M. et al. Impact of body mass index on heart failure by race/ethnicity from the Get With The Guidelines-Heart Failure (GWTG-HF) registry. JACC Heart Fail. 6, 233–242 (2018).
pubmed: 29428434
pmcid: 5834392
doi: 10.1016/j.jchf.2017.11.011
Butt, J. H. et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur. Heart J. 44, 1136–1153 (2023).
pubmed: 36944496
pmcid: 10111968
doi: 10.1093/eurheartj/ehad083
Kamimura, D. et al. Cigarette smoking and incident heart failure. Circulation 137, 2572–2582 (2018).
pubmed: 29661945
pmcid: 6085757
doi: 10.1161/CIRCULATIONAHA.117.031912
Morris, P. B. et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American College of Cardiology. J. Am. Coll. Cardiol. 66, 1378–1391 (2015).
pubmed: 26383726
doi: 10.1016/j.jacc.2015.07.037
Levitzky, Y. S. et al. Relation of smoking status to a panel of inflammatory markers: the Framingham offspring. Atherosclerosis 201, 217–224 (2008).
pubmed: 18289552
pmcid: 2783981
doi: 10.1016/j.atherosclerosis.2007.12.058
Bye, A. et al. Carbon monoxide levels experienced by heavy smokers impair aerobic capacity and cardiac contractility and induce pathological hypertrophy. Inhal. Toxicol. 20, 635–646 (2008).
pubmed: 18464052
doi: 10.1080/08958370701883821
Ambrose, J. A. & Barua, R. S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol. 43, 1731–1737 (2004).
pubmed: 15145091
doi: 10.1016/j.jacc.2003.12.047
Hall, M. E. et al. Cigarette smoking and chronic kidney disease in African Americans in the Jackson Heart Study. J. Am. Heart Assoc. 5, e003280 (2016).
pubmed: 27225196
pmcid: 4937270
doi: 10.1161/JAHA.116.003280
Brouwers, F. P. et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur. Heart J. 34, 1424–1431 (2013).
pubmed: 23470495
doi: 10.1093/eurheartj/eht066
Johansson, I. et al. Health-related quality of life and mortality in heart failure: the Global Congestive Heart Failure study of 23 000 patients from 40 countries. Circulation 143, 2129–2142 (2021).
pubmed: 33906372
doi: 10.1161/CIRCULATIONAHA.120.050850
Vedin, O. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a Nationwide Cohort Study. Circ. Heart Fail. 10, e003875 (2017).
pubmed: 28615366
doi: 10.1161/CIRCHEARTFAILURE.117.003875
Docherty, K. F. et al. Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991-2016. Eur. J. Heart Fail. 25, 1213–1224 (2023).
pubmed: 37401485
doi: 10.1002/ejhf.2965
Yandrapalli, S. et al. Sex differences in heart failure hospitalisation risk following acute myocardial infarction. Heart 107, 1657–1663 (2021).
pubmed: 33431424
doi: 10.1136/heartjnl-2020-318306
Damasceno, A., Cotter, G., Dzudie, A., Sliwa, K. & Mayosi, B. M. Heart failure in sub-Saharan Africa: time for action. J. Am. Coll. Cardiol. 50, 1688–1693 (2007).
pubmed: 17950152
doi: 10.1016/j.jacc.2007.07.030
Izumi, C. et al. In-hospital outcomes of heart failure patients with valvular heart disease: insights from real-world claims data. Clinicoecon. Outcomes Res. 15, 349–360 (2023).
pubmed: 37223825
pmcid: 10202112
doi: 10.2147/CEOR.S405079
Arora, S. et al. Prevalence and prognostic significance of mitral regurgitation in acute decompensated heart failure: The ARIC Study. JACC Heart Fail. 9, 179–1895 (2021).
pubmed: 33309575
doi: 10.1016/j.jchf.2020.09.015
Watkins, D. A. et al. Global, regional, and National burden of rheumatic heart disease, 1990-2015. N. Engl. J. Med. 377, 713–722 (2017).
pubmed: 28834488
doi: 10.1056/NEJMoa1603693
Hazebroek, M., Dennert, R. & Heymans, S. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth. Heart J. 20, 332–335 (2012).
pubmed: 22618228
pmcid: 3402574
doi: 10.1007/s12471-012-0285-7
Hershberger, R. E. et al. Genetic evaluation of cardiomyopathy — a Heart Failure Society of America practice guideline. J. Card. Fail. 15, 83–97 (2009).
pubmed: 19254666
doi: 10.1016/j.cardfail.2009.01.006
Schulze-Bahr, E., Klaassen, S., Abdul-Khaliq, H. & Schunkert, H. Molecular diagnostics of cardiovascular diseases: expert consensus statement by the German Cardiac Society (DGK) and the German Society of Pediatric Cardiology (DGPK). Der Kardiologe 9, 213–243 (2015).
doi: 10.1007/s12181-014-0636-2
Gigli, M. et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 74, 1480–1490 (2019).
pubmed: 31514951
pmcid: 6750731
doi: 10.1016/j.jacc.2019.06.072
Halliday, B. P. et al. Sex‐and age‐based differences in the natural history and outcome of dilated cardiomyopathy. Eur. J. Heart Fail. 20, 1392–1400 (2018).
pubmed: 29862606
doi: 10.1002/ejhf.1216
Maron, B. J., Rowin, E. J., Udelson, J. E. & Maron, M. S. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail. 6, 353–363 (2018).
pubmed: 29655822
doi: 10.1016/j.jchf.2017.09.011
Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249–1254 (2015).
pubmed: 25814232
doi: 10.1016/j.jacc.2015.01.019
Maron, B. J. et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J. Am. Coll. Cardiol. 65, 1915–1928 (2015).
pubmed: 25953744
doi: 10.1016/j.jacc.2015.02.061
Rastegar, H. et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann. Cardiothorac. Surg. 6, 353 (2017).
pubmed: 28944176
pmcid: 5602194
doi: 10.21037/acs.2017.07.07
Lopes, L. R. et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. Eur. Heart J. Qual. Care Clin. Outcomes 9, 42–53 (2023).
doi: 10.1093/ehjqcco/qcac006
Bloom, M. W. et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ. Heart Fail. 9, e002661 (2016).
pubmed: 26747861
pmcid: 4709035
doi: 10.1161/CIRCHEARTFAILURE.115.002661
Narayan, H. K. et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135, 1397–1412 (2017).
pubmed: 28104715
pmcid: 5388560
doi: 10.1161/CIRCULATIONAHA.116.023463
Saiki, H. et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135, 1388–1396 (2017).
pubmed: 28132957
pmcid: 5388583
doi: 10.1161/CIRCULATIONAHA.116.025434
Bern, C. & Montgomery, S. P. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49, e52–54 (2009).
pubmed: 19640226
doi: 10.1086/605091
Nunes, M. C. P. et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation 138, e169–e209 (2018).
pubmed: 30354432
doi: 10.1161/CIR.0000000000000599
No authors listed.Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol. Rec. 90, 33–43 (2015).
Chadalawada, S. et al. Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis. Esc. Heart Fail. 8, 5466–5481 (2021).
pubmed: 34716744
pmcid: 8712892
doi: 10.1002/ehf2.13648
AbouEzzeddine, O. F. et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 6, 1267–1274 (2021).
pubmed: 34431962
doi: 10.1001/jamacardio.2021.3070
González-López, E. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 36, 2585–2594 (2015).
pubmed: 26224076
doi: 10.1093/eurheartj/ehv338
Mohammed, S. F. et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2, 113–122 (2014).
pubmed: 24720917
pmcid: 3984539
doi: 10.1016/j.jchf.2013.11.004
Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann. Med. 40, 232–239 (2008).
pubmed: 18382889
doi: 10.1080/07853890701842988
Kittleson, M. M. et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142, e7–e22 (2020).
pubmed: 32476490
doi: 10.1161/CIR.0000000000000792
Shah, K. S. et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J. Am. Coll. Cardiol. 70, 2476–2486 (2017).
pubmed: 29141781
doi: 10.1016/j.jacc.2017.08.074
Crespo-Leiro, M. G. et al. European Society of Cardiology Heart Failure Long-Term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur. J. Heart Fail. 18, 613–625 (2016).
pubmed: 27324686
doi: 10.1002/ejhf.566
Kimmoun, A. et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur. J. Heart Fail. 23, 420–431 (2021).
pubmed: 33443295
doi: 10.1002/ejhf.2103
Schmidt, M., Ulrichsen, S. P., Pedersen, L., Bøtker, H. E. & Sørensen, H. T. Thirty-year trends in heart failure hospitalization and mortality rates and the prognostic impact of co-morbidity: a Danish nationwide cohort study. Eur. J. Heart Fail. 18, 490–499 (2016).
pubmed: 26868921
doi: 10.1002/ejhf.486
Glynn, P., Lloyd-Jones, D. M., Feinstein, M. J., Carnethon, M. & Khan, S. S. Disparities in cardiovascular mortality related to heart failure in the United States. J. Am. Coll. Cardiol. 73, 2354–2355 (2019).
pubmed: 31072580
doi: 10.1016/j.jacc.2019.02.042
Youn, Y. J. et al. Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: report from the Korean Heart Failure Registry. Circ. J. 76, 1151–1158 (2012).
pubmed: 22343195
doi: 10.1253/circj.CJ-11-1093
Sato, N. et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am. Heart J. 159, 949–955 (2010).
pubmed: 20569705
doi: 10.1016/j.ahj.2010.03.019
Hariharaputhiran, S. et al. Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand. Eur. J. Heart Fail. 24, 1519–1528 (2022).
pubmed: 35748124
doi: 10.1002/ejhf.2595
Hsich, E. M. et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am. Heart J. 163, 430–437 (2012).
pubmed: 22424014
doi: 10.1016/j.ahj.2011.12.013
Jain, V. et al. Demographic and regional trends of heart failure-related mortality in young adults in the US, 1999-2019. JAMA Cardiol. 7, 900–904 (2022).
pubmed: 35895048
pmcid: 9330269
doi: 10.1001/jamacardio.2022.2213
Siddiqi, T. J. et al. Trends in heart failure-related mortality among older adults in the United States from 1999-2019. JACC Heart Fail. 10, 851–859 (2022).
pubmed: 36328654
doi: 10.1016/j.jchf.2022.06.012
Buddeke, J. et al. Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men. BMC Public Health 20, 36 (2020).
pubmed: 31924185
pmcid: 6954619
doi: 10.1186/s12889-019-7934-3
Clark, K. A. A. et al. Trends in heart failure hospitalizations in the US from 2008 to 2018. J. Card. Fail. 28, 171–180 (2022).
pubmed: 34534665
doi: 10.1016/j.cardfail.2021.08.020
Taylor, C. J., Roalfe, A. K., Iles, R. & Hobbs, F. D. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur. J. Heart Fail. 14, 176–184 (2012).
pubmed: 22253455
doi: 10.1093/eurjhf/hfr170
Zhang, Y. et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) Registry. J. Card. Fail. 23, 868–875 (2017).
pubmed: 29029965
doi: 10.1016/j.cardfail.2017.09.014
Tsuchihashi-Makaya, M. et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ. J. 73, 1893–1900 (2009).
pubmed: 19644216
doi: 10.1253/circj.CJ-09-0254
Nieminen, M. S. et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart J. 27, 2725–2736 (2006).
pubmed: 17000631
doi: 10.1093/eurheartj/ehl193
Salah, H. M. et al. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. Esc. Heart Fail. 9, 947–952 (2022).
pubmed: 35098700
pmcid: 8934991
doi: 10.1002/ehf2.13823
Jain, V. et al. Trends in HF hospitalizations among young adults in the United States from 2004 to 2018. JACC Heart Fail. 10, 350–362 (2022).
pubmed: 35483798
doi: 10.1016/j.jchf.2022.01.021
Savitz, S. T. et al. Contemporary reevaluation of race and ethnicity with outcomes in heart failure. J. Am. Heart Assoc. 10, e016601 (2021).
pubmed: 33474975
pmcid: 7955425
doi: 10.1161/JAHA.120.016601
Rosano, G. M. C. et al. Impact analysis of heart failure across European countries: an ESC-HFA position paper. Esc. Heart Fail. 9, 2767–2778 (2022).
pubmed: 35869679
pmcid: 9715845
doi: 10.1002/ehf2.14076
Sulo, G. et al. Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) project. Eur. J. Heart Fail. 22, 241–248 (2020).
pubmed: 31646725
doi: 10.1002/ejhf.1609
National Institute for Health and Care Excellence (NICE). Chronic Heart Failure in Adults: Diagnosis and Management. NICE Guideline https://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685 (2018).
Lawson, C. A. et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health 4, e406–e420 (2019).
pubmed: 31376859
pmcid: 6686076
doi: 10.1016/S2468-2667(19)30108-2
Vaduganathan, M. et al. Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiol. 6, 1415–1423 (2021).
pubmed: 34524394
doi: 10.1001/jamacardio.2021.3651
Escobar, C. et al. Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. J. Clin. Med. 11, 5199 (2022).
pubmed: 36079133
pmcid: 9456780
doi: 10.3390/jcm11175199
Heo, S. et al. Changes in heart failure symptoms are associated with changes in health-related quality of life over 12 months in patients with heart failure. J. Cardiovasc. Nurs. 33, 460–466 (2018).
pubmed: 29697502
doi: 10.1097/JCN.0000000000000493
Napier, R. et al. Comparing measures to assess health-related quality of life in heart failure with preserved ejection fraction. JACC Heart Fail. 6, 552–560 (2018).
pubmed: 29885952
pmcid: 6026057
doi: 10.1016/j.jchf.2018.02.006
Garin, O. et al. Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. Qual. Life Res. 22, 2675–2684 (2013).
pubmed: 23677481
doi: 10.1007/s11136-013-0383-z
Kosiborod, M. et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation 115, 1975–1981 (2007).
pubmed: 17420346
doi: 10.1161/CIRCULATIONAHA.106.670901
Moser, D. K. et al. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. J. Card. Fail. 15, 763–769 (2009).
pubmed: 19879462
pmcid: 2772831
doi: 10.1016/j.cardfail.2009.05.003
Chan, P. S. et al. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 119, 398–407 (2009).
pubmed: 19139382
doi: 10.1161/CIRCULATIONAHA.108.820472
Luo, N. et al. Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. Eur. J. Heart Fail. 21, 63–70 (2019).
pubmed: 30168635
doi: 10.1002/ejhf.1299
Sepehrvand, N. et al. Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure. J. Am. Heart Assoc. 9, e017278 (2020).
pubmed: 32812460
pmcid: 7660771
doi: 10.1161/JAHA.120.017278
Lawson, C. A. et al. Changing health related quality of life and outcomes in heart failure by age, sex and subtype. EClinicalMedicine 64, 102217 (2023).
pubmed: 37745020
pmcid: 10514432
doi: 10.1016/j.eclinm.2023.102217
Shahid, I., Khan, M. S., Fonarow, G. C., Butler, J. & Greene, S. J. Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure. Prog. Cardiovasc. Dis. 82, 61–69 (2024).
pubmed: 38244825
doi: 10.1016/j.pcad.2024.01.008
Bassi, N. S., Ziaeian, B., Yancy, C. W. & Fonarow, G. C. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 5, 948–951 (2020).
pubmed: 32374344
doi: 10.1001/jamacardio.2020.0898
Greene, S. J. et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J. Am. Coll. Cardiol. 72, 351–366 (2018).
pubmed: 30025570
doi: 10.1016/j.jacc.2018.04.070
Pierce, J. B. et al. Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get with the Guidelines-Heart Failure Registry. JAMA Cardiol. 8, 652–661 (2023).
pubmed: 37212192
pmcid: 10203967
doi: 10.1001/jamacardio.2023.1266
Tromp, J. et al. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. Eur. Heart J. 43, 2224–2234 (2022).
pubmed: 35393622
doi: 10.1093/eurheartj/ehac103
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
pubmed: 34449189
doi: 10.1056/NEJMoa2107038
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J. Am. Coll. Cardiol. 79, e263–e4212 (2022).
pubmed: 35379503
doi: 10.1016/j.jacc.2021.12.012
Kumar, R. K. et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. Circulation 142, e337–e357 (2020).
pubmed: 33073615
doi: 10.1161/CIR.0000000000000921
Spertus, J. A. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397, 2467–2475 (2021).
pubmed: 34004177
doi: 10.1016/S0140-6736(21)00763-7
Burton, A. et al. Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des. Devel. Ther. 15, 1225–1243 (2021).
pubmed: 33776421
pmcid: 7987260
doi: 10.2147/DDDT.S289772
Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007–1016 (2018).
pubmed: 30145929
doi: 10.1056/NEJMoa1805689
Bibbins-Domingo, K. et al. Racial differences in incident heart failure among young adults. N. Engl. J. Med. 360, 1179–1190 (2009).
pubmed: 19297571
pmcid: 2829671
doi: 10.1056/NEJMoa0807265
Cook, C., Cole, G., Asaria, P., Jabbour, R. & Francis, D. P. The annual global economic burden of heart failure. Int. J. Cardiol. 171, 368–376 (2014).
pubmed: 24398230
doi: 10.1016/j.ijcard.2013.12.028
Joseph, P. et al. A multinational registry to study the characteristics and outcomes of heart failure patients: the Global Congestive Heart Failure (G-CHF) registry. Am. Heart J. 227, 56–63 (2020).
pubmed: 32679282
doi: 10.1016/j.ahj.2020.06.002
Wang, N., Hales, S., Barin, E. & Tofler, G. Characteristics and outcome for heart failure patients with mid-range ejection fraction. J. Cardiovasc. Med. 19, 297–303 (2018).
doi: 10.2459/JCM.0000000000000653